Welcome to the Wyoming Chapter of the American College of Cardiology
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- ACC CardiaCast: Innovation in Action: Leveraging Wearables in Cardiovascular CareIn this episode, ACC Chief Innovation Officer Dr. Ami Bhatt and Dr. Sanket Dhruva explore how wearables are shaping the future of personalized care.
- POLY-HF: Daily Polypill Boosts Heart Function, QOL, and Cuts Hospitalizations in Underserved Patients With HFrEFA polypill combination of three medications typically prescribed for heart failure (HF), once daily for six months, improved heart function and symptoms, quality of life and medication adherence, as well as reduced hospitalizations, in patients with HF with reduced ejection fraction (HFrEF) and facing socioeconomic disadvantages.
- CorCMR: Stress CMR Imaging May Help Improve Diagnosis and Treatment of AnginaStress cardiac magnetic resonance (CMR)-guided management of patients with chest pain and nonobstructive coronary artery disease was superior to angiography-guided management alone in correctly diagnosing microvascular angina and improving chest pain symptoms and quality of life after six months to one year...
- TUXEDO-2: Ticagrelor vs. Prasugrel in Patients With Diabetes and Multivessel Disease After PCIIn patients with diabetes and multivessel coronary artery disease undergoing PCI, a ticagrelor-based dual antiplatelet therapy (DAPT) regimen did not offer the same level of benefit at preventing heart attack, stroke, bleeding complications or death as a prasugrel-based DAPT regimen...
- CELEBRATE: Zalunfiban vs. Placebo at First Medical Contact in Patients With STEMI?A single subcutaneous injection of zalunfiban administered on first medical contact with patients with suspected STEMI was associated with improved patency of the infarct-related artery at index angiography and a significantly lower chance of all-cause death, stroke, recurrent myocardial infarction (MI)...